Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gregory Renza

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug

Acadia notched a win in a patent battle Wednesday pertaining to its Parkinson's drug and ACAD stock soared to a four-month high.

Investors Business Daily

The Surprise That Prompted Morphic Therapeutic To Dump 55% Over Two Days

Morphic stock plummeted Monday after the company's ulcerative colitis drug underperformed a rival. MORF stock has lost 55% over two days.

Investors Business Daily

Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High

Acadia obliterated expectations for the launch quarter of its Rett syndrome treatment and, on Friday, ACAD stock hit a two-year high.

Investors Business Daily

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Investors Business Daily

Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

Investors Business Daily

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest

Seagen Chief Executive Clay Siegall resigned Monday amid domestic violence allegations, and SGEN stock inched up.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.